Lilly’s Zepbound Outperforms Wegovy in Obesity Trial, Published in NEJM

Eli Lilly's Zepbound (tirzepatide) delivered significantly greater weight loss than Novo Nordisk’s Wegovy (semaglutide) in the head-to-head SURMOUNT-5 trial, according to results published May 11 in *The New England Journal of Medicine*. Over 72 weeks, Zepbound users lost an average of 20.2% of their body weight versus 13.7% with Wegovy. Zepbound also outperformed on all secondary endpoints, including percentage achieving major weight-loss thresholds and waist circumference reduction. The results, presented at the European Congress on Obesity, further position Zepbound as a leading obesity treatment.